AEterna Zentaris (AEZS) Stock Investors are making great fortune at the moment – Here’s how!

  • Twitter
  • Facebook
  • Google+
  • Pinterest

Æterna Zentaris Inc, a biopharmaceutical drug development Canada-based company is enjoying the limelight in the stocks market right now as its shares, all of a sudden, boosted up to 23% earlier today and currently trading on heavy volume, causing the investments flooding in and raising the demand simultaneously.

Thanks to FDA who approved a new drug application of AEZS related to Macrilen which is a drug treatment used for the evaluation of adult growth hormone deficiency (AGHD). Macrilen was having a hard time receiving a favorable ruling from the United States Food and Drug Administration but after the news broke out about FDA considering Macrilen by AEZC to be accepted, instantly doubled the shares of this bio-pharmaceutical company.

However, the final decision about the respective drug approval is still underway and expected to be announced by the Prescription Drug User Fee Act (PDUFA) on December 30th this year.  According to a statement by David Didd, CEO at AEZS, the company is confident about the approval of NDA by FDA and they are ready to move forward with their preparations to launch the product in the first quarter of 2018.

This is not the only reason traders are investing in AEZC stocks for, the bio-pharmaceutical is going all lucky these days as another good news was received from the Maxim group as the analyst firm maintained their buying rate by increasing the price target from $2.00 to $4.00 per share on the stock.

Investors understand that after the approval of Macrilen for growth hormone deficiency, the company will receive a tremendous amount of value in its stock. Why are they so sure about this? It is because Macrilen, as suggested by the doctors, is another effective test used for AGHD and it is safer than the insulin tolerance test, the only AGHD test existing. Analysts and Doctors believe that Macrilen will certainly advance the treatment of AGHD and related health issues.

Now Macrilen by AEZC being this close to getting FDA-approved and renowned in the market, seems like a safe spot for shareholders in stocks these days. But keep a close eye on AEZC, its moves and the stocks if choosing to get into it through marketwatch , because this how the stock market works, right? Be vigilant!

error: Content is protected !!